SCHERING's IMDUR HAD 26% OF GROWING ISOSORBIDE MONONITRATE MARKET
SCHERING's IMDUR HAD 26% OF GROWING ISOSORBIDE MONONITRATE MARKET in the six months ended Sept. 30, according to data from IMS America's NPA Plus data service. On a more than four-fold jump in scripts in its second six-month period on the U.S. market, Imdur generated 316,000 scripts between April and September of this year. In its first six-month period on the market, the product generated 73,000 scripts. In retail dollars, Imdur generated over $8 mil. in sales in the March-September period.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth